An uncontrolled trial of cytisine (Tabex) for smoking cessation

Witold Zatonski, Magdalena Cedzynska, Piotr Tutka and Robert West

Tob. Control 2006;15:481-484
doi:10.1136/tc.2006.016097

Updated information and services can be found at:
http://tc.bmj.com/cgi/content/full/15/6/481

References
These include:
This article cites 10 articles, 1 of which can be accessed free at:
http://tc.bmj.com/cgi/content/full/15/6/481#BIBL

Rapid responses
You can respond to this article at:
http://tc.bmj.com/cgi/eletter-submit/15/6/481

Email alerting service
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

Topic collections
Articles on similar topics can be found in the following collections
Smoking cessation (250 articles)

Notes

To order reprints of this article go to:
http://www.bmjournals.com/cgi/reprintform

To subscribe to Tobacco Control go to:
http://www.bmjournals.com/subscriptions/
BRIEF REPORT

An uncontrolled trial of cytisine (Tabex) for smoking cessation

Witold Zatonski, Magdalena Cedzynska, Piotr Tutka, Robert West

Objectives: Cytisine (Tabex) has been licensed in Eastern Europe as an aid to smoking cessation for 40 years. Cytisine is a partial agonist with high affinity binding to the α4β2 nicotinic acetylcholine receptor believed to be central to the rewarding effect of nicotine. There is insufficient information on effectiveness to warrant licensing by modern standards. To assess whether full-scale controlled trials are warranted, this study sought to obtain an estimate of the 12-month continuous abstinence rates of smokers using cytisine with minimal behavioural support.

Design: An uncontrolled, open-label trial.

Setting: A smokers’ clinic in an oncology centre in Warsaw, Poland.

Subjects: 436 consecutive attendees of the smokers’ clinic of whom 191 were male. The mean dependence score (Fagerstrom Test for Nicotine Dependence) was 6.1.

Intervention: The standard regimen of Tabex (cytisine) was used, involving 25 days of treatment with minimal behavioural support.

Main outcome measure: Self-reported continuous abstinence for 12 months; with abstinence verified by carbon monoxide at the final follow up after 12 months.

Results: 60 participants (13.8% of the total sample) were abstinent for 12 months. Of the 315 subjects, who had taken the drug, 49 (15.5%) stopped cytisine because of adverse effects (mostly gastric disturbances and nausea), although they were not serious. The frequency of the minor adverse effects, primarily gastric disturbance, was similar to that observed in previous studies with the drug.

Conclusions: The long-term abstinence rates were similar to those observed in smokers receiving nicotine replacement therapy. Full-scale randomised trials of cytisine (Tabex), conducted to the standards required by regulatory authorities, are warranted.

Nicotine replacement therapy (NRT) and bupropion increase 12-month continuous abstinence rates of smokers making a quit attempt by 5–14%, depending on the context. Other medications have also been found to aid cessation, most notably nortriptyline. New medications in the pipeline are varenicline (Pfizer) and rimonabant (Sanofi-Aventis). Nicotine vaccines are undergoing clinical trials. Behavioural support can improve the chances of success of quit attempts by an estimated 2–7%.

The cost of smoking cessation treatments is an important issue. The cost per life-year gained compares very favourably with other medical treatments, but most healthcare systems and many smokers, even in richer countries, do not feel that they can afford the current forms of treatment. If a much cheaper form of treatment exists that is as effective, it is important to evaluate it. One such medication is Tabex.
2470 smokers were allocated to receive one of 16 drugs, of whom 520 were treated with Tabex or placebo. After three months 25% of those on Tabex reported abstinence in a postal questionnaire compared with 21% on placebo (p > 0.05).18 It was not clear how smokers were assigned to conditions.

No serious adverse effects were reported in the trials but the documentation and design of these studies would not be considered sufficient to support registration in European countries because of, among other things, lack of longer-term follow-up, clear definitions of sustained abstinence, and absence of biochemical verification. However, the data do suggest that the drug is safe and efficacious. There is a need to undertake a rigorous evaluation of its safety and efficacy using outcome criteria that are widely accepted in the field.

As a first step to this, we have undertaken an open label uncontrolled trial of use of the drug in a smokers' clinic in Warsaw. Smokers attending the clinic were prescribed the recommended course of treatment and followed up using Russell Standard criteria for 12 months. If 12-month continuous abstinence rates were observed that were substantially higher than the figure of 2–10% seen in placebo groups of other clinical trials1 or in smokers attempting to stop unaided,20 there would be a strong prima facie case for effectiveness and this would merit moving rapidly to full scale placebo-controlled randomised controlled trials. In an evaluation of the UK stop smoking services, a programme of scale placebo-controlled randomised controlled trials. In an evaluation of the UK stop smoking services, a programme of smokers attended just one session of behavioural support. The >6 month continuous abstinence rates in the active treatment group of these NRT trials was 14%. An abstinence rate similar to this would suggest therapeutic efficacy.

METHODS

This was an open, uncontrolled trial in the form of a clinical audit. A total of 438 consecutive attendees at the stop smoking clinic at the cancer institute in Warsaw between 17 November and 27 December 2003 took part. The stop smoking clinic provides a service to the local community and is provided free of charge. Smokers were considered for admission into the trial if they were seeking help with stopping smoking at the clinic. Smokers were excluded if they were judged by the consulting physician to be contra-indicated for Tabex. The exclusion criteria were: active stomach ulcer, uncontrolled hypertension, adrenal hypertrophy, and receiving treatment for a psychiatric disorder. Two smokers were excluded by these criteria. Eligible patients were informed about the study and provided verbal consent. A total of 436 patients were included.

The treatment programme consisted of one session before quitting and the offer of other sessions to those that wanted it. The main session involved a nurse collecting demographic information and measuring blood pressure, heart rate, height, weight, and expired-air carbon monoxide concentration (CO). The patients then completed a questionnaire on nicotine dependence (Fagerstrom Test for Nicotine Dependence (FTND)22). Then the patient was seen by a physician who took a smoking and medical history and obtained informed consent from eligible patients. The physician provided information about Tabex, including the usage regimen and side effects. Patients then received individually tailored advice on stopping smoking and written support materials. Patients were offered follow-up visits as required by the patient. The session lasted approximately 30 minutes in total. Follow-up visits, where they occurred, lasted about 20 minutes and did not follow a formal structure.

Tabex is administered orally in a dose of 1 tablet every 2 hours (6 tablets daily) for three days while smokers reduce the number of smoked cigarettes. The treatment then proceeds according to the following scheme: from the 4th to 12th day—1 tablet every 2.5 hours (5 tablets daily); from the 13th to 16th day—1 tablet every 3 hours (4 tablets daily); from 17th to 20th—1 tablet every 4 hours (3 tablets daily), from the 21st to 25th day—1 tablet every 6 hours, 1–2 tablets daily. Smokers were instructed that they should have stopped smoking completely by the fifth day. The average duration of taking medication was 22 days. The duration of the course of medication was shorter than for medication such as bupropion or nicotine replacement therapies, but this was a clinical audit of the treatment regimen currently licensed and it would not have been appropriate to operate outside the licence.

Participants were followed up at 12 weeks with up to one additional week needed to make contact. Those who reported being abstinent at 12 weeks were followed up at 12 months with up to an additional two months needed to make contact. The 12-week follow-up involved only telephone contact. Participants were asked whether they were currently smoking and whether they had smoked at all since the quit date, how far they had followed the treatment regimen and about any adverse events. The 12-month follow-up involved an initial telephone contact; participants who reported that they had not smoked since the 12-week follow-up were invited to attend the clinic for CO verification. Participants who were unable to attend the clinic were offered a home visit.

Outcome was assessed using the Russell Standard.21 This standard is designed to facilitate comparison of outcome figures across studies. It involves 12 months of continuous abstinence recorded at the 12-month follow-up and supported at that follow-up by CO < 10 ppm. The Russell Standard allows reporting of up to five cigarettes during the follow-up window but in the present study only reports of complete abstinence were counted as successes. All smokers allocated to receive the treatment are included in the analysis and any participants that cannot be followed up are considered to have resumed smoking.

RESULTS

Table 1 shows the sample characteristics. The participants were similar in smoking and demographic profile to those found in clinical trials in the United States and United Kingdom.1 Their FTND (dependence) score was slightly older age than is typically found in US and UK studies. The majority of participants attended just one session.

Three hundred and forty-two smokers were successfully followed up by telephone at 12 weeks. Of these 315 indicated that they had taken at least one tablet of Tabex. One hundred and twenty participants (27.5%) of the total sample reported having not smoked at all since the quit date. When these participants were followed up at 12 months, 60 (13.8% of the original sample) reported having been abstinent for the preceding 12 months and were confirmed as abstinent by CO at the follow-up.

A total of 13.8% of those attending the smokers’ clinic reported being continuously abstinent for 12 months at follow-up with their current smoking status confirmed by CO concentration. It may be noted that there were 27 participants who reported at follow-up that they had not taken any medication and all of these had returned to

www.tobaccocontrol.com
smoking; all participants (98) who could not be contacted were assumed to be smoking.

At the 12-week follow-up patients were asked about known nicotine withdrawal symptoms using a check list and any other adverse events using an open response format. The most frequently reported withdrawal symptoms were: irritability (36%), restlessness (23%), depression (15%), appetite increase (47%), and sleep disturbance (21%). Constipation occurred in less than 10% of patients but they were more frequently observed among those who quit (13% v 6%). The most frequently reported adverse events were mouth dryness (35%), nausea and gastric disturbances (6%). The most frequently reported withdrawal symptoms were: mouth dryness (35%), nausea and gastric disturbances (10%). Of the 315 subjects who had taken the drug, 31 (15.5%) reported that they stopped because of adverse effects, 31 due to nausea and gastric disturbances.

**DISCUSSION**

The 12-month success rate was similar to the figure observed in the evaluation of the UK smoking cessation services. This was despite the fact that the smokers were more dependent on average, as indicated by the FTND, and most only attended one session of psychological support.

There may be many reasons for the high success rate in the Polish study, other than treatment using Tabex, but the absolute percentage figure, together with clinical data used to register the product, gives strong a priori grounds for believing that the drug is effective. The six-month sustained quit rates register the product, give strong a priori grounds for believing that the drug is effective. The six-month sustained quit rates were 8% but there were studies that had claimed the drug is effective. The 12-month success rate was similar to the figure observed in the evaluation of the UK smoking cessation services. This underscored the fact that the smokers were more dependent on average, as indicated by the FTND, and most only attended one session of psychological support.

There were no reported serious adverse events. The numbers reporting minor adverse events was higher than the figure for NRTs. However, without a direct comparison caution should be exercised in interpreting this figure. Taken together with the results from earlier studies these findings support the argument for a drug evaluation programme undertaken to modern standards. This would include large scale clinical trials of this drug to a standard that would be acceptable by regulatory authorities around the world. More information is also required on the pharmacokinetic properties of the drug, its safety profile and ideally studies varying the dose and the duration of dose. The obvious advantage of this medication is its cost. It offers the prospect of providing access to effective treatment to help with smoking cessation to millions of smokers who would otherwise not be able to afford it.

**What this paper adds**

Cytisine, medication licensed in Eastern Europe for 40 years as an aid to smoking cessation, appears to improve abstinence rates in smokers attempting to stop. Existing studies, however, have not included long-term follow-up or have adopted inadequate abstinence criteria.

The 12-month carbon monoxide verified continuous abstinence rate following a standard course of treatment with cytisine with minimal behavioural support was found in 436 smokers to be similar (13.8%) to that observed following treatment with nicotine replacement therapy. Full scale randomised controlled trials could lead to widespread adoption of this drug which, because of its cost, could make effective treatment available to millions of smokers that would otherwise not be able to afford it.

**ACKNOWLEDGEMENTS**

We would like to express our thanks to Sopharma for supplying the Tabex.

We would like to thank, as well, all staff members who worked daily in the clinic—doctors: Elzbieta Karpinska, Dorota Lewandowska, Joanna Jonska, Joanna Surowinska, Ewelina Bobek-Pstrucha; and nurses: Katarzyna Marczyk, Dorota Sadowska, Zofia Kociszewska.
CONTRIBUTORS
Witold Zatonski: overall concept of the trial, planning, preparation and supervision of work done in trial, participation in analysis and editing the paper. Magdalena Cedzynska: participation in planning the observation, everyday controlling works doing in clinic, participation in analysis data and editing the paper. Piotr Tutka: participation in drafting and editing the paper. Robert West: participation in designing the follow-ups, analysis and drafting and editing the paper.

References


